USD
$0.00
(0.00%
)At Close (As of Sep 3, 2025)
$159.26M
Market Cap
-
P/E Ratio
-4.75
EPS
$8.25
52 Week High
$1.46
52 Week Low
LIFE SCIENCES
Sector
Field | Value (USD) |
---|---|
Gross Profit | $65M |
Total Revenue | $65M |
Cost Of Revenue | $383K |
Costof Goods And Services Sold | $383K |
Operating Income | $15M |
Selling General And Administrative | $23M |
Research And Development | $17M |
Operating Expenses | $35M |
Investment Income Net | - |
Net Interest Income | $3.3M |
Interest Income | $3.3M |
Interest Expense | - |
Non Interest Income | - |
Other Non Operating Income | - |
Depreciation | - |
Depreciation And Amortization | $383K |
Income Before Tax | $18M |
Income Tax Expense | $7.6M |
Interest And Debt Expense | - |
Net Income From Continuing Operations | $18M |
Comprehensive Income Net Of Tax | - |
Ebit | $18M |
Ebitda | $18M |
Net Income | $18M |
Field | Value (USD) |
---|---|
Total Assets | $41M |
Total Current Assets | $41M |
Cash And Cash Equivalents At Carrying Value | $3.7M |
Cash And Short Term Investments | $3.7M |
Inventory | - |
Current Net Receivables | - |
Total Non Current Assets | $606K |
Property Plant Equipment | - |
Accumulated Depreciation Amortization Ppe | - |
Intangible Assets | - |
Intangible Assets Excluding Goodwill | - |
Goodwill | - |
Investments | - |
Long Term Investments | - |
Short Term Investments | $35M |
Other Current Assets | $2.4M |
Other Non Current Assets | - |
Total Liabilities | $8.4M |
Total Current Liabilities | $8.4M |
Current Accounts Payable | $3.2M |
Deferred Revenue | - |
Current Debt | - |
Short Term Debt | - |
Total Non Current Liabilities | $0 |
Capital Lease Obligations | $0 |
Long Term Debt | - |
Current Long Term Debt | - |
Long Term Debt Noncurrent | - |
Short Long Term Debt Total | - |
Other Current Liabilities | $5.2M |
Other Non Current Liabilities | - |
Total Shareholder Equity | $33M |
Treasury Stock | - |
Retained Earnings | -$388M |
Common Stock | - |
Common Stock Shares Outstanding | $6.7M |
Field | Value (USD) |
---|---|
Operating Cashflow | -$50M |
Payments For Operating Activities | - |
Proceeds From Operating Activities | - |
Change In Operating Liabilities | - |
Change In Operating Assets | - |
Depreciation Depletion And Amortization | $383K |
Capital Expenditures | $7K |
Change In Receivables | - |
Change In Inventory | - |
Profit Loss | - |
Cashflow From Investment | $49M |
Cashflow From Financing | -$12M |
Proceeds From Repayments Of Short Term Debt | - |
Payments For Repurchase Of Common Stock | - |
Payments For Repurchase Of Equity | - |
Payments For Repurchase Of Preferred Stock | - |
Dividend Payout | $12M |
Dividend Payout Common Stock | $12M |
Dividend Payout Preferred Stock | - |
Proceeds From Issuance Of Common Stock | - |
Proceeds From Issuance Of Long Term Debt And Capital Securities Net | - |
Proceeds From Issuance Of Preferred Stock | - |
Proceeds From Repurchase Of Equity | - |
Proceeds From Sale Of Treasury Stock | - |
Change In Cash And Cash Equivalents | - |
Change In Exchange Rate | - |
Net Income | $18M |
Field | Value (USD) |
---|---|
Gross Profit | $65M |
Total Revenue | $65M |
Cost Of Revenue | $383K |
Costof Goods And Services Sold | $383K |
Operating Income | $15M |
Selling General And Administrative | $23M |
Research And Development | $17M |
Operating Expenses | $35M |
Investment Income Net | - |
Net Interest Income | $3.3M |
Interest Income | $3.3M |
Interest Expense | - |
Non Interest Income | - |
Other Non Operating Income | - |
Depreciation | - |
Depreciation And Amortization | $383K |
Income Before Tax | $18M |
Income Tax Expense | $7.6M |
Interest And Debt Expense | - |
Net Income From Continuing Operations | $18M |
Comprehensive Income Net Of Tax | - |
Ebit | $18M |
Ebitda | $18M |
Net Income | $18M |
Field | Value |
---|---|
Ex Dividend Date | 2023-11-16 |
Declaration Date | 2023-11-06 |
Record Date | 2023-11-17 |
Payment Date | 2023-12-06 |
Amount | 1.75 |
Sector: LIFE SCIENCES
Industry: PHARMACEUTICAL PREPARATIONS
MEI Pharma, Inc., an advanced stage pharmaceutical company, focuses on the development of various therapies for the treatment of cancer. The company is headquartered in San Diego, California.